MỐI LIÊN QUAN GIỮA BỆNH GAN NHIỄM MỠ CHUYỂN HOÁ VÀ MỨC ĐỘ XƠ HOÁ GAN ĐÁNH GIÁ BẰNG FIBROTOUCH

Abstract

Objective: This study aimed to investigate the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and liver fibrosis severity assessed by FibroTouch, and to evaluate the predictive value of non-invasive indices APRI and FIB-4 in fibrosis risk stratification. Methods: A cross-sectional study was conducted on 256 adult patients with complete data on FibroTouch, APRI, FIB-4, and MAFLD status. Patients were categorized by fibrosis stages (F0–F4). Ordinal logistic regression was used to identify factors associated with higher stages of liver fibrosis. Results: The mean age was 70,02 ± 8.81 years; 66% were male. The prevalence of MAFLD was 51%. The proportion of MAFLD increased with fibrosis severity, from 44% in F0-F1 to 83% in F4 (p = 0,001). Liver enzymes (ALT, AST, GGT), APRI, and FIB-4 levels significantly increased across fibrosis stages. In ordinal logistic regression, MAFLD was independently associated with higher fibrosis severity (OR = 3.07; 95% CI: 1.71–5.68; p = 0,0002). Low-risk APRI was associated with a significantly lower risk of advanced fibrosis (OR = 0,03; 95% CI: 0,001–0,50; p = 0,017). High-risk FIB-4 tended to increase fibrosis risk but did not reach statistical significance (p = 0,102). Conclusion: MAFLD is a significant independent predictor of advanced liver fibrosis. APRI and FIB-4 are useful non-invasive tools for fibrosis risk stratification, especially in patients with MAFLD